Filing Flows › Neurocrine Biosciences (NBIX) › Guidance & outlook
Neurocrine Biosciences (NBIX) guidance and outlook
Neurocrine Biosciences (NBIX) raised its guidance on Nov 2, 2026: Revenue $2.9B for FY2026; Stock-based compensation $115M for FY2026. Neurocrine Biosciences' 10-Q filed Nov 2, 2026 makes 3 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $2.9B | raised |
| Stock-based compensation | FY2026 | $115M | reaffirmed |
From the earnings release filed Nov 2, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 2, 2026
- We estimate that TD affects approximately 800,000 people in the U.S., that approximately 90% of the 40,000 people in the U.S. affected by Huntington’s disease will develop chorea, that CAH affects at least 20,000 people in the U.S., and that hyperphagia in PWS affects approximately 10,000 people in the U.S.
- However, we cannot guarantee that our existing capital resources and anticipated revenues will be sufficient to conduct and complete all of our research and development programs or commercialization activities as planned.
- However, we cannot provide assurance that adequate funding will be available on terms acceptable to us, if at all.
Neurocrine Biosciences' latest quarter
Neurocrine Biosciences, Q3 2026: revenue $1.1B (+41% year over year), operating margin 29.5%, net earnings $206M, operating cash flow $395M. The chart follows the revenue to costs, profit and cash.
Questions
Did Neurocrine Biosciences raise or lower its guidance?
Neurocrine Biosciences (NBIX) raised its guidance on Nov 2, 2026: Revenue $2.9B for FY2026; Stock-based compensation $115M for FY2026.
What does Neurocrine Biosciences expect?
We estimate that TD affects approximately 800,000 people in the U.S., that approximately 90% of the 40,000 people in the U.S. affected by Huntington’s disease will develop chorea, that CAH affects at least 20,000 people in the U.S., and that hyperphagia in PWS affects approximately 10,000 people in the U.S. However, we cannot guarantee that our existing capital resources and anticipated revenues will be sufficient to conduct and complete all of our research and development programs or commercialization activities as planned. However, we cannot provide assurance that adequate funding will be av
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.